InflaRx develops new therapeutics in the field of acute and chronic inflammation.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Jena
State: Thuringen
Zip:
Country: Germany
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
11/8/2017
IPO Valuation:
$351M
Ticker Symbol:
IFRX
IPO Price:
$15/share
Amount Raised:
$100M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|